Therefore, it seems plausible to speculate that mINDY might be an interesting target for the treatment of metabolic disease, such as obesity, non-alcoholic fatty liver disease and type 2 diabetes [48, 107, 108]. This evidence concerns the gene SLC13A5 and metabolic dysfunction-associated steatotic liver disease.